IDEXX Laboratories Inc

IDXX is in a Stage 2 advancing phase with price holding above rising short-term EMAs, signaling repaired structure and a bullish medium-term bias. The absence of active bearish patterns and low transition risk support continuation. Short-term timing favors entry now as price pulls back into the 9 and 21 EMA support zone without visible exhaustion. We recommend a Buy Now near dynamic support to participate in the ongoing advance.

• ↑Q1 revenue rose 14% to $1.3 B, with 11% organic growth
• ↑EBITDA margin expanded to 32.3% on operational efficiency gains
• ↓U.S. same-store clinical visits fell 1%, pressuring wellness revenue